Amarin Corp. PLC won its first big recommendation from a physician group for the use of Vascepa with inclusion of its proprietary fish oil derivative in American Diabetes Association (ADA) guidelines for the treatment of diabetes patients with atherosclerotic cardiovascular disease (ASCVD).
The March 27 ADA announcement was followed by Amarin's own news on March 28 that it has now completed a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
